Clinical phenotypes and endophenotypes of atopic dermatitis: Where are we, and where should we go?
Thomas Bieber,Thomas Bieber,Angelo Massimiliano D'Erme,Cezmi A. Akdis,Claudia Traidl-Hoffmann,Roger Lauener,Georg Schäppi,Peter Schmid-Grendelmeier +7 more
Reads0
Chats0
TLDR
A systems biology approach merging the numerous clinical phenotypes with robust biomarkers will be needed to best exploit their potential significance for the future molecular taxonomy of AD.Abstract:
Atopic dermatitis (AD) is a paradigmatic chronic inflammatory skin disease characterized by a complex pathophysiology and a wide spectrum of the clinical phenotype. Despite this high degree of heterogeneity, AD is still considered a single disease and usually treated according to the "one-size-fits-all" approach. Thus more tailored prevention and therapeutic strategies are still lacking. As for other disciplines, such as oncology or rheumatology, we have to approach AD in a more differentiated way (ie, to dissect and stratify the complex clinical phenotype into more homogeneous subgroups based on the endophenotype [panel of biomarkers]) with the aim to refine the management of this condition. Because we are now entering the era of personalized medicine, a systems biology approach merging the numerous clinical phenotypes with robust (ie, relevant and validated) biomarkers will be needed to best exploit their potential significance for the future molecular taxonomy of AD. This approach will not only allow an optimized prevention and treatment with the available drugs but also hopefully help assign newly developed medicinal products to those patients who will have the best benefit/risk ratio.read more
Citations
More filters
Journal ArticleDOI
Early-onset-early-resolving atopic dermatitis does not increase the risk of development of allergic diseases at 3 Years old.
Li-Chieh Wang,Bor-Luen Chiang +1 more
TL;DR: The early-onset-early-resolving AD was not associated with allergic diseases development at age 3, and the parental atopy history and early-ONSet-persistent AD might be the risk factors for development of allergic diseases at age3.
Journal ArticleDOI
Atopic dermatitis in West Highland white terriers - part I: natural history of atopic dermatitis in the first three years of life.
TL;DR: This longitudinal study of puppies from a predisposed breed sheds new light on the early development of cAD in WHWTs.
Journal ArticleDOI
Potential biomarkers of atopic dermatitis
Ling Yu,Linfeng Li +1 more
TL;DR: In this paper , the authors summarized the current development of potential biomarkers of atopic dermatitis (AD) and proposed several potential predictors or predictors have been found, including NOS2/iNOS, human beta-defensin-2 (hBD-2), and matrix metalloproteinases 8/9 (MMP8/9) for AD diagnosis.
Journal ArticleDOI
Atopic dermatitis: molecular, cellular, and clinical aspects
Jafar Salimian,Zahra Salehi,Ali Ahmadi,Alireza Emamvirdizadeh,Seyyed Masoud Davoudi,Mehrdad Karimi,Mohsen Korani,Sadegh Azimzadeh Jamalkandi +7 more
TL;DR: The dynamic immunological responses, genetic susceptibilities, and structural modifications associated with AD's pathophysiology will be extensively discussed in this review, each according to the latest achievements and findings.
Journal ArticleDOI
Precision medicine in atopic diseases.
TL;DR: Precision medicine is aiming to use known endotype phenotype to guide specific individualized treatment in atopic diseases in light of the availability of ever more precise treatment able to target specific pathways.
References
More filters
Journal ArticleDOI
Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework*
Arthur J. Atkinson,Wayne A. Colburn,Victor G. DeGruttola,David L. DeMets,Gregory J. Downing,Daniel F. Hoth,John A. Oates,Carl C. Peck,Robert T. Schooley,Bert A. Spilker,Janet Woodcock,Scott L. Zeger +11 more
TL;DR: Biomarker measurements provide an avenue for researchers to gain a mechanistic understanding of the differences in clinical response that may be influenced by uncontrolled variables (for example, drug metabolism).
Journal ArticleDOI
The Endophenotype Concept in Psychiatry: Etymology and Strategic Intentions
TL;DR: The authors discuss the etymology and strategy behind the use of endophenotypes in neuropsychiatric research and, more generally, in research on other diseases with complex genetics.
Journal ArticleDOI
Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis
Colin N. A. Palmer,Alan D. Irvine,Ana Terron-Kwiatkowski,Yiwei Zhao,Haihui Liao,Simon P. Lee,David Goudie,Aileen Sandilands,Linda E. Campbell,Frances J.D. Smith,Grainne M. O'Regan,Rosemarie Watson,Jo E Cecil,Sherri J. Bale,John G. Compton,John J. DiGiovanna,John J. DiGiovanna,Philip Fleckman,Sue Lewis-Jones,Gehan Arseculeratne,Ann Sergeant,Colin S. Munro,Brahim El Houate,Ken McElreavey,Liselotte Brydensholt Halkjaer,Hans Bisgaard,Somnath Mukhopadhyay,Somnath Mukhopadhyay,W.H. Irwin McLean +28 more
TL;DR: It is shown that two independent loss-of-function genetic variants (R510X and 2282del4) in the gene encoding filaggrin (FLG) are very strong predisposing factors for atopic dermatitis.
Journal ArticleDOI
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Eric L. Simpson,Thomas Bieber,Emma Guttman-Yassky,Lisa A. Beck,Andrew Blauvelt,Michael J. Cork,Jonathan I. Silverberg,Mette Deleuran,Yoko Kataoka,Jean-Philippe Lacour,Külli Kingo,Margitta Worm,Margitta Worm,Yves Poulin,Andreas Wollenberg,Yuhwen Soo,Neil M.H. Graham,Gianluca Pirozzi,Bolanle Akinlade,Heribert Staudinger,Vera Mastey,Laurent Eckert,Abhijit Gadkari,Neil Stahl,George D. Yancopoulos,Marius Ardeleanu +25 more
TL;DR: Dupilumab improved the signs and symptoms of atopic dermatitis, including pruritus, symptoms of anxiety and depression, and quality of life, as compared with placebo in two phase 3 trials of identical design.
Related Papers (5)
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Eric L. Simpson,Thomas Bieber,Emma Guttman-Yassky,Lisa A. Beck,Andrew Blauvelt,Michael J. Cork,Jonathan I. Silverberg,Mette Deleuran,Yoko Kataoka,Jean-Philippe Lacour,Külli Kingo,Margitta Worm,Margitta Worm,Yves Poulin,Andreas Wollenberg,Yuhwen Soo,Neil M.H. Graham,Gianluca Pirozzi,Bolanle Akinlade,Heribert Staudinger,Vera Mastey,Laurent Eckert,Abhijit Gadkari,Neil Stahl,George D. Yancopoulos,Marius Ardeleanu +25 more
Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.
Lisa A. Beck,Diamant Thaçi,Jennifer D. Hamilton,Neil M.H. Graham,Thomas Bieber,Ross E. Rocklin,Jeffrey Ming,Haobo Ren,Richard Kao,Eric L. Simpson,Marius Ardeleanu,Steven P. Weinstein,Gianluca Pirozzi,Emma Guttman-Yassky,Mayte Suárez-Fariñas,Melissa D. Hager,Neil Stahl,George D. Yancopoulos,Allen Radin +18 more
Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis
Colin N. A. Palmer,Alan D. Irvine,Ana Terron-Kwiatkowski,Yiwei Zhao,Haihui Liao,Simon P. Lee,David Goudie,Aileen Sandilands,Linda E. Campbell,Frances J.D. Smith,Grainne M. O'Regan,Rosemarie Watson,Jo E Cecil,Sherri J. Bale,John G. Compton,John J. DiGiovanna,John J. DiGiovanna,Philip Fleckman,Sue Lewis-Jones,Gehan Arseculeratne,Ann Sergeant,Colin S. Munro,Brahim El Houate,Ken McElreavey,Liselotte Brydensholt Halkjaer,Hans Bisgaard,Somnath Mukhopadhyay,Somnath Mukhopadhyay,W.H. Irwin McLean +28 more